Evidence map›Paper›PMID 38091231›Full record

Observational studyInternational journal of hematology2024

Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).

Kensuke Usuki, Shigeki Ohtake, Sumihisa Honda, Mitsuhiro Matsuda, Atsushi Wakita, Yuichiro Nawa, Ken Takase, Akio Maeda, Nobuo Sezaki, Hisayuki Yokoyama and 20 more

Abstract readObservational StudyMulticenter Study
PubMed Publisher
In one paragraph

Observational study in International journal of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Kensuke UsukiDepartment of Hematology, NTT Medical Center Tokyo, Higashi-Gotanda 5-9-22, Shinagawa-ku, Tokyo, 141-8625, Japan. kensuke.usuki@gmail.com.ORCID http://orcid.org/0000-0002-1216-4470
Shigeki OhtakeKanazawa University, Kanazawa, Japan.
Sumihisa HondaNagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Mitsuhiro MatsudaPL General Hospital, Tondabayashi, Osaka, Japan.
Atsushi WakitaNagoya City University East Medical Center, Nagoya, Japan.
Yuichiro NawaDivision of Hematology, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Ken TakaseKyushu Medical Center, Fukuoka, Japan.
Akio MaedaHyogo Cancer Center, Akashi, Japan.
Nobuo SezakiChugoku Central Hospital, Fukuyama, Japan.
Hisayuki YokoyamaNational Hospital Organization Sendai Medical Center, Sendai, Japan.
Satoru TakadaLeukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan.
Daiki HiranoDepartment of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Tatsuki TomikawaDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
Masahiko SumiNagano Red Cross Hospital, Nagano, Japan.
Shingo YanoDivision of Clinical Oncology and Hematology, The Jikei University School of Medicine, Tokyo, Japan.
Hiroshi HandaGunma University, Maebashi, Japan.
Shuichi OtaSapporo Hokuyu Hospital, Sapporo, Japan.
Hiroyuki FujitaDepartment of Hematology, Yokohama Nanbu Hospital, Yokohama, Japan.
Katsumichi FujimakiDepartment of Hematology, Fujisawa City Hospital, Kanagawa, Japan.
Atsuko MugitaniFuchu Hospital Division of Hematology, Osaka, Japan.
Kensuke KojimaDepartment of Hematology, Kochi Medical School, Kochi University, Nankoku, Japan.
Tomohiro KajiguchiDepartment of Hematology and Oncology, Tosei General Hospital, Seto, Japan.
Ko FujimotoDepartment of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka, Japan.
Norio AsouInternational Medical Center, Saitama Medical University, Hidaka, Japan.
Noriko UsuiDepartment of Clinical Oncology and Hematology, The Jikei University Daisan Hospital, Tokyo, Japan.
Yuichi IshikawaDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Akira KatsumiDepartment of Hematology, National Center for Geriatrics and Gerontology, Obu, Japan.
Itaru MatsumuraDepartment of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka, Japan.
Yasushi MiyazakiDepartment of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Hitoshi KiyoiDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Funding

Japan Agency for Medical Research and Development AMED (22ck0106251h0003)
6 · The paper itself

Abstract

We conducted a multicenter, prospective observational study of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia (CMML) in Japan. From August 2011 to January 2016, we enrolled 6568 patients. Herein, we report the results for MDS (n = 2747) and CMML (n = 182). The percentage of patients aged 65 years or older was 79.5% for MDS and 79.7% for CMML. The estimated overall survival (OS) rate and cumulative incidence of AML evolution at 5 years were 32.3% (95% confidence interval: 30.2-34.5%) and 25.7% (23.9-27.6%) for MDS, and 15.0% (8.9-22.7%) and 39.4% (31.1-47.6%) for CMML. Both diseases were more common in men. The most common treatment for MDS was azacitidine, which was used in 45.4% of higher-risk and 12.7% of lower-risk MDS patients. The 5-year OS rate after treatment with azacitidine was 12.1% (9.5-15.1%) for of higher-risk MDS patients and 33.9% (25.6-42.4%) for lower-risk patients. The second most common treatment was erythropoiesis-stimulating agents, given to just 20% of lower-risk patients. This is the first paper presenting large-scale, Japanese data on survival and clinical characteristics in patients with MDS and CMML.

Indexed as

Leukemia, Myeloid, AcuteLeukemia, Myelomonocytic, ChronicMyelodysplastic SyndromesAntimetabolites, AntineoplasticAzacitidineHumansJapanMaleAntimetabolites, AntineoplasticAzacitidineAML evolutionChronic myelomonocytic leukemiaEpidemiologyMyelodysplastic syndromesSurvival

Identifiers

PMID38091231

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.